Victor Moreno, Director Clinical Research at START Madrid FJD, shared on LinkedIn:
”A few months ago, during the ASCO Plenary Session, the audience rose to give a standing ovation to the daraxonrasib results in pancreatic cancer.
Today, July 23, the article appears in the print edition of The New England Journal of Medicine. A paper that has transformed the treatment landscape in pancreatic cancer, and whose print publication also happens to coincide with my birthday.
Some birthday presents come wrapped in NEJM.”
Title: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
Authors: Eileen M. O’Reilly, Zev A. Wainberg, Andrew E. Hendifar, Mitesh J. Borad, Filippo Pietrantonio, Shubham Pant, Pascal Hammel, Chiara Cremolini, Gulam A. Manji, Paul E. Oberstein, Ignacio Garrido-Laguna, Christoph Springfeld, Nilofer S. Azad, Makoto Ueno, Stephen Y. Chui, Ying Zhang, Hina Patel, Yeonju Lee, Zeena Salman, Brian M. Wolpin
Other articles about Pancreatic cancer on OncoDaily.